1. Home
  2. GRFS vs CORT Comparison

GRFS vs CORT Comparison

Compare GRFS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • CORT
  • Stock Information
  • Founded
  • GRFS 1940
  • CORT 1998
  • Country
  • GRFS Spain
  • CORT United States
  • Employees
  • GRFS N/A
  • CORT N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • CORT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRFS Health Care
  • CORT Health Care
  • Exchange
  • GRFS Nasdaq
  • CORT Nasdaq
  • Market Cap
  • GRFS 6.6B
  • CORT 7.6B
  • IPO Year
  • GRFS 2006
  • CORT N/A
  • Fundamental
  • Price
  • GRFS $9.11
  • CORT $70.86
  • Analyst Decision
  • GRFS Hold
  • CORT Strong Buy
  • Analyst Count
  • GRFS 1
  • CORT 4
  • Target Price
  • GRFS $10.30
  • CORT $139.00
  • AVG Volume (30 Days)
  • GRFS 592.2K
  • CORT 938.9K
  • Earning Date
  • GRFS 01-01-0001
  • CORT 11-04-2025
  • Dividend Yield
  • GRFS 1.58%
  • CORT N/A
  • EPS Growth
  • GRFS 132.60
  • CORT N/A
  • EPS
  • GRFS 0.53
  • CORT 1.11
  • Revenue
  • GRFS $8,744,226,659.00
  • CORT $716,080,000.00
  • Revenue This Year
  • GRFS $5.46
  • CORT $28.85
  • Revenue Next Year
  • GRFS $6.69
  • CORT $34.98
  • P/E Ratio
  • GRFS $22.60
  • CORT $63.79
  • Revenue Growth
  • GRFS 9.32
  • CORT 25.71
  • 52 Week Low
  • GRFS $6.19
  • CORT $47.63
  • 52 Week High
  • GRFS $11.14
  • CORT $117.33
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 36.85
  • CORT 38.04
  • Support Level
  • GRFS $9.14
  • CORT $70.89
  • Resistance Level
  • GRFS $9.50
  • CORT $74.25
  • Average True Range (ATR)
  • GRFS 0.29
  • CORT 2.71
  • MACD
  • GRFS -0.02
  • CORT -0.46
  • Stochastic Oscillator
  • GRFS 26.39
  • CORT 11.12

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Share on Social Networks: